Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

Podcast: OncLive® On Air · OncLive® On Air

Opublikowano: 2026-10-14

In today’s episode, we spoke with Angeles Alvarez Secord, MD, MHSc. Dr Secord is a professor of obstetrics and gynecology and a member of Duke Cancer Institute in Durham, North Carolina. In our exclusive interview, Dr Secord discussed the emergence of B7-H4 as an attractive antibody-drug conjugate (ADC) target in gynecologic cancers, noting that expression rates of 80% to 90% or higher across endometrial and ovarian cancers distinguish it favorably from other targets such as folate receptor α and HER2, where high expression thresholds are often required for meaningful benefit. She also highlighted a mechanistic distinction: unlike FRα- or...